41736 - Cancer (Answered)

David Tredinnick
To ask the Secretary of State for Health, if he will take steps to review the decision to remove peptide receptor radionuclide therapy treatments from the Cancer Drugs Fund list.

George Freeman

The National Institute for Health and Care Excellence (NICE) is currently appraising the peptide receptor radionuclide therapy treatment lutetium-177-DOTA octreotate for the treatment of neuroendocrine tumours and for gastroenteropancreatic neuroendocrine tumours.

NHS England has advised that it will await the outcome of NICE’s appraisals before making any commissioning decisions on peptide receptor radionuclide therapy treatments.

In the meantime, if a patient’s condition is considered clinically exceptional, then an application can be considered under NHS England’s Individual Funding Request system.